Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2003
06/26/2003US20030119858 Conformationally constrained compounds as pharmaceutical agents
06/26/2003US20030119838 Water-soluble phenylpyridazine compounds and compositions containing the same
06/26/2003US20030119837 Pharmaceutical composition for the treatment of CNS and other disorders
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119834 Angiogenesis inhibitors; 3-alkyl-4-one quinazoline derivatives
06/26/2003US20030119830 Monocyte chemoattractant protein-1 inhibitor compounds
06/26/2003US20030119829 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions
06/26/2003US20030119827 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
06/26/2003US20030119826 Neuroprotective treatment methods using selective iNOS inhibitors
06/26/2003US20030119822 Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119811 Ion channel antagonists that are NMDA antagonists; treatment of migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.
06/26/2003US20030119800 Administering an ANGELS (Activators of Non-Genotropic Estrogen-like Signaling compound"ANGELS") compound to maintain or increase bone mass, bone density and/or bone strength.
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119766 Antisense modulation of apolipoprotein (A) expression
06/26/2003US20030119748 Use for treatment of inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
06/26/2003US20030119746 Treatment of both primary and metastatic solid tumors
06/26/2003US20030119742 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
06/26/2003US20030119719 Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
06/26/2003US20030119718 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
06/26/2003US20030119717 Synergistic activation of regulatory elements by rel proteins and a steroid receptor
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119168 Diagnosis of anticancer agents using nucleic acids
06/26/2003US20030119148 Amino-terminally truncated rantes as chemokine antagonists
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119036 Isolated nucleic acids; anticholesterol agents, cardiovascular disorders, antiinflammatory agents, antilipemic agents
06/26/2003US20030118990 Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
06/26/2003US20030118988 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
06/26/2003US20030118652 Methods and compositions for use of (S)-bisoprolol
06/26/2003US20030118648 Two combined tablet portions, with different releasing rates; drug delivery providing immediate, sustained and prolonged release
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118633 Treating unstable or overactive urinary bladder by administering an antimuscarinic agent and an estrogen agonist
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118551 Modified viral surface proteins for binding to extracellular matrix components
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2473938A1 Human adam-10 inhibitors
06/26/2003CA2473877A1 Substituted beta-aminoalcohols as pharmaceutical preparations
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2471500A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003CA2470811A1 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003CA2470723A1 3,4-dihydro-1h-isoquinolin-2-yl-derivatives
06/26/2003CA2470616A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003CA2470491A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2470479A1 Polymorphs of clopidogrel hydrogensulfate
06/26/2003CA2470311A1 Method of screening compounds
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2470210A1 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003CA2470060A1 Improvements in pharmaceutical compositions
06/26/2003CA2469976A1 Improvements in pharmaceutical compositions
06/26/2003CA2469950A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003CA2469799A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003CA2469786A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003CA2469305A1 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
06/26/2003CA2469302A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2460806A1 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1321526A2 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
06/25/2003EP1321522A1 Promoting cell survival by inhibiting BARD1 apoptotic activity
06/25/2003EP1321169A1 Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
06/25/2003EP1321148A1 Cyclotetrasaccharide for augmenting "active-oxygen-eliminating-activity"
06/25/2003EP1321032A1 Method of constructing heart failure model animal
06/25/2003EP1320710A1 Drying method for selectively removing volatile components from wet coatings
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320601A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320589A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320545A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
06/25/2003EP1320536A1 $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES
06/25/2003EP1320532A1 Tetrapyrroles
06/25/2003EP1320531A2 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/25/2003EP1320530A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
06/25/2003EP1320528A2 Substituted phthalides as anti-convulsive drugs
06/25/2003EP1320526A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
06/25/2003EP1320523A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/25/2003EP1320521A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(en)oic acid as therapeutic agents
06/25/2003EP1320520A1 Sulfonylguanidine
06/25/2003EP1320371A2 Charged phospholipid compositions and methods for their use
06/25/2003EP1320363A1 Lactone integrin antagonists
06/25/2003EP1263470B1 METHOD FOR PRODUCING A COENZYME Q10 / $g(g)-CYCLODEXTRIN COMPLEX
06/25/2003EP1178981B1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
06/25/2003EP1169313B1 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
06/25/2003EP1025086B1 Benzamidine derivatives as factor xa inhibitors
06/25/2003EP1000008B1 Novel thyroid receptor ligands and method
06/25/2003EP0966282B1 Use of the angiotensin ii antagonists losartan and exp-3174 to treat symptomatic heart failure
06/25/2003EP0946546B1 Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine
06/25/2003EP0874824B1 Tri-substituted phenyl derivatives useful as pde iv inhibitors
06/25/2003EP0840615B1 Chemokine binding protein and methods of use therefor
06/25/2003EP0808172B1 Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy
06/25/2003EP0777652B1 Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
06/25/2003EP0726074B1 Method for obtaining apolar and polar extracts of curcuma and applications thereof
06/25/2003EP0641343B1 4-mercaptoacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
1 ... 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 ... 1595